Table 2.
Primary and Secondary Outcomes
| General Population (n = 709) | Hematologic Malignancy (n = 124) | P value | |
|---|---|---|---|
| Venous Thromboembolism (VTE) | .069 | ||
| Yes | 3.6% (16) | 8.0% (9) | |
| No | 96.4% (428) | 92% (103) | |
| Cerebrovascular Accident (CVA) | .011 | ||
| Yes | 1.6% (7) | 5.4% (6) | |
| No | 98.4% (437) | 93.8% (105) | |
| Composite VTE/CVA | .005 | ||
| Yes | 5.2% (23) | 13.4% (15) | |
| No | 94.8% (421) | 86.6% (97) | |
| Fatality Rate | 11.3% (80) | 35.5% (44) | <.001 |
| Respiratory Support | <.001 | ||
| None | 53.5% (379) | 25.4% (29) | |
| Nasal Cannula (NC)/ Non-rebreather (NRB) | 29.3% (208) | 36.0% (41) | |
| High Flow Nasal Cannula (HFNC) | 4.9% (35) | 20.2% (23) | |
| Non-invasive Positive Pressure Ventilation (NIPPV)/ Intubated | 12.3% (87) | 18.4% (21) | |
| ICU Admission | 12.1% (128) | 31.9% (36) | .001 |
| ICU Duration (days, median [IQR]) | 5 [3.0, 13.0] | 6 [4.0, 12.5] | .192 |
| Ventilator Duration (days, median [IQR]) | 6 [3.0, 12.5] | 8[4.0, 17.0] | .326 |
Abbreviations: IQR = interquartile range.